# 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer

> **NCT00081276** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 48 (actual)

## Conditions studied

- Primary Peritoneal Cavity Cancer
- Recurrent Ovarian Epithelial Cancer
- Stage III Ovarian Epithelial Cancer
- Stage IV Ovarian Epithelial Cancer

## Interventions

- **DRUG:** triapine
- **DRUG:** cisplatin
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00081276
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2007-01
- **Final completion:** —
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2013-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00081276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00081276, "3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00081276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*